Andrew Morgenstern, OD, FAAO, FNAP, President and Co-founder of IKA, talked about his session at the meeting that discussed the prevalence of keratoconus in the pediatric population in the US.

Catch up on what happened in optometry during the week of May 13-May 17.

William Reindel, OD, discusses how pupil size affects fit and comfort in multifocal contact lens wearers.

EyeCon chair Kelly K. Nichols, OD, PhD, MPH, FAAO, shares some of her favorite moments throughout her career and what inspires her to continue pushing the industry forward.

The SCANLY Home OCT device allows physicians to monitor patients’ wet age-related macular degeneration in between visits through a health cloud portal.

The microemulsion drug ocular penetration system platform technology was found to effectively formulate and deliver lipophilic molecules via topical eye drops.

The Early Detection of Vision Impairment in Children (EDVI) Act was recently introduced in the US House of Representatives with the goal of improving access, diagnosis, and treatment for children ages 2 to 17, according to Prevent Blindness.

Considering recovery time, potential adverse effects, and future eye care needs can increase patient satisfaction.

Noel Brennan, MScOptom, PhD, overviews his ARVO 2024 presentation on reimagining the prediction of longer term efficacy numbers in data from pediatric trials evaluating myopia.

Preventive options should be as important as treating symptoms

A team of Chinese researchers have been working on a way to continuously and more comfortably detect these tiny fluctuations in pressure, such as contact lenses that transmit signals to receptor glasses.

The company reported that statistically significant data was found supporting ANX007’s ability to provide vision loss protection in patients with geographic atrophy.

Honest discussions about treatments for dry eye disease can enhance compliance and simplify care.

Catch up on what happened in optometry during the week of May 6-May 10.

The clinical-stage biopharmaceutical company has enrolled 15 participants in its study to assess the safety and tolerability of ACT107 in 3 dose strengths.

Conditionally accepted by the FDA as EYO-1901, DURAVYU is a tyrosine kinase inhibitor intended to improve signs and symptoms of non-proliferative diabetic retinopathy in the PAVIA trial.

The diagnostic aid platform, C.DIAG, utilizes artificial intelligence to assist with the diagnosis and treatment of dry eye disease.

Marjorie Rah, OD, PhD, FAAO, discussed the in-home use test of BioTrue Hydration Plus multipurpose contact lens solution (Bausch + Lomb) on patients who are considering lens dropout.

Selina McGee, OD, FAAO, shares an overview of a panel on Thyroid Eye Disease that took place at Controversies in Modern Eye Care.

Melissa Tawa, OD, FAAO, chats about glaucoma case studies, surgical interventions, and appropriate technology choices based on patients at the 18th Annual Controversies in Modern Eye Care meeting.